Neonatal screening for congenital adrenal hyperplasia
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Congenital adrenal hyperplasia (CAH) is well suited for newborn screening, as it is a common and potentially fatal disease which can be easily diagnosed by a simple hormonal measurement in blood. Moreover, early recognition and treatment can prevent severe salt wasting, dehydration and death and shorten the time of male sex assignment in virilised females.In screening programmes, 17alpha-hydroxyprogesterone (17OHP) is measured in filter paper blood spots obtained by a heel puncture preferably between 2 and 4 days after birth. Three assay techniques are utilised for initial screening: radio-immunoassay (USA), enzyme-linked immunosorbent assay (Japan) and time-resolved fluoro-immunoassay (Europe). Preterm newborns have higher 17OHP concentrations in serum than babies born at term. Therefore, cut-off levels are based on gestational age (in Japan and Europe) or on birth weight (in the USA). There is a considerable variation in cut-off levels from one programme to another. This is most likely due to the different antibodies and reagents used, varying thickness and density of filter paper used for sample collection and, most significantly, the characteristics of the reference population (in terms of birth weight and gestational age). More than 30 million newborns have been screened. The prevalence of CAH in the USA and Europe is approximately 1:15 000-16 000, and slightly lower in Japan (1:19 000). In general, severe salt wasting can be prevented, but there is a remarkable variation in the number of false-positives and false-negatives among the various programmes. Ongoing refinement of cut-off levels is needed to improve specificity and sensitivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The delay before correct sex assignment of severely virilized females is also markedly reduced (233).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [233]
In the citing paper
“Based on a classic CAH incidence of 1:10,000 to 1:20,000 (23, 43, 44, 52), 1:50 to 1:71 people in the general population are heterozygotes.”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [23]
Citations
Cites
Principles and Practice of Screening for Disease.
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-69-5-1085_2 · Cited by 3,066
A SIMPLE PHENYLALANINE METHOD FOR DETECTING PHENYLKETONURIA IN LARGE POPULATIONS OF NEWBORN INFANTS
Guthrie, R., & Susi, A. (1963) · Pediatrics · doi:10.1542/peds.32.3.338 · Cited by 2,219
Therrell, B. L., Berenbaum, S. A., Manter-Kapanke, V., Simmank, J., Korman, K., Prentice, L., Gonzalez, J., & Gunn, S. (1998) · Pediatrics · doi:10.1542/peds.101.4.583 · Cited by 344
PANG, S., HOTCHKISS, J., DRASH, A. L., LEVINE, L. S., & NEW, M. I. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-45-5-1003 · Cited by 293
Brosnan, C. A., Brosnan, P., Therrell, B. L., Slater, C. H., Swint, J. M., Annegers, J. F., & Riley, W. J. (1998) · Europe PMC (PubMed Central) · Cited by 201
A Pilot Newborn Screening for Congenital Adrenal Hyperplasia in Alaska*
PANG, S., MURPHEY, W., LEVINE, L. S., SPENCE, D. A., LEON, A., LAFRANCHI, S., SURVE, A. S., & NEW, M. I. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-55-3-413 · Cited by 157
Allen, D. B., Hoffman, G. L., Fitzpatrick, P., Laessig, R., Maby, S., & Slyper, A. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70321-4 · Cited by 153
Thilén, A., Nordenström, A., Hagenfeldt, L., von Döbeln, U., Guthenberg, C., & Larsson, A. (1998) · PEDIATRICS · doi:10.1542/peds.101.4.e11 · Cited by 151
U.S. Newborn Screening Policy Dilemmas for the Twenty-First Century
Therrell, B. L. (2001) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2001.3238 · Cited by 119
Balsamo, A., Cacciari, E., Piazzi, S., Cassio, A., Bozza, D., Pirazzoli, P., & Zappulla, F. (1996) · PEDIATRICS · doi:10.1542/peds.98.3.362 · Cited by 116
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Genetics of congenital adrenal hyperplasia
Krone, N., & Arlt, W. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.014 · Cited by 312
PW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
Neonatal screening for congenital adrenal hyperplasia
White, P. C. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.148 · Cited by 240
Finkielstain, G. P., Chen, W., Mehta, S. P., Fujimura, F. K., Hanna, R. M., Van Ryzin, C., McDonnell, N. B., & Merke, D. P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0319 · Cited by 192
Clinical guidelines for the management of adrenal incidentaloma
Lee, J.-M., Kim, M. K., Ko, S.-H., Koh, J.-M., Kim, B.-Y., Kim, S. W., Kim, S.-K., Kim, H. J., Ryu, O.-H., Park, J., et al. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.2.200 · Cited by 147
Management of adolescents with congenital adrenal hyperplasia
Merke, D. P., & Poppas, D. P. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70138-4 · Cited by 134
How Many Deaths Can Be Prevented by Newborn Screening for Congenital Adrenal Hyperplasia?
Grosse, S. D., & Van Vliet, G. (2007) · Hormone Research in Paediatrics · doi:10.1159/000098400 · Cited by 102
Genetics of Congenital Adrenal Hyperplasia
Hannah-Shmouni, F., Chen, W., & Merke, D. P. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.01.008 · Cited by 97
The Complexities in Genotyping of Congenital Adrenal Hyperplasia: 21-Hydroxylase Deficiency
Pignatelli, D., Carvalho, B. L., Palmeiro, A., Barros, A., Guerreiro, S. G., & Macut, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00432 · Cited by 95
Parajes, S., Quinteiro, C., Domínguez, F., & Loidi, L. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002138 · Cited by 87
Newborn screening for congenital adrenal hyperplasia in New Zealand, 1994-2013
Heather, N. L., Seneviratne, S. N., Webster, D., Derraik, J. G. B., Jefferies, C., Carll, J., Jiang, Y., Cutfield, W. S., & Hofman, P. L. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3168 · Cited by 65
Congenital adrenal hyperplasia and the second newborn screen
Chan, C. L., McFann, K., Taylor, L., Wright, D., Zeitler, P. S., & Barker, J. M. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2013.01.002 · Cited by 46
The cost effectiveness of screening newborns for congenital adrenal hyperplasia
Yoo, B. K., & Grosse, S. D. (2009) · Public Health Genomics · doi:10.1159/000156115 · Cited by 37
Xu, C., Jia, W., Cheng, X., Ying, H., Chen, J., Xu, J., Guan, Q., Zhou, X., Zheng, D., Li, G., et al. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.671 · Cited by 29
“The classic forms of 21OHD occur in 1 in 15,000 newborns, while the prevalence of the nonclassic form of 21OHD is estimated to be 1 in 1,000 individuals (Pang & Shook, 1997; Speiser et al., 2018; Therrell, 2001; van der Kamp & Wit, 2004).”
BackgroundEvaluation of the Dutch neonatal screening for congenital adrenal hyperplasia
van der Linde, A. A. A., Schönbeck, Y., van der Kamp, H. J., van den Akker, E. L. T., van Albada, M. E., Boelen, A., Finken, M. J. J., Hannema, S. E., Hoorweg-Nijman, G., Odink, R. J., et al. (2019) · Archives of Disease in Childhood · doi:10.1136/archdischild-2018-315972 · Cited by 32
Ekman, B., Fitts, D., Marelli, C., Murray, R. D., Quinkler, M., & Zelissen, P. M. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-40 · Cited by 31
Jiang, X., Tang, F., Feng, Y., Li, B., Jia, X., Tang, C., Liu, S., & Huang, Y. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2019-0140 · Cited by 21
on behalf of the German Society of Pediatric Endocrinology and Diabetology, Dörr, H. G., Wollmann, H. A., Hauffa, B. P., & Woelfle, J. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0263-1 · Cited by 22
Bertholf, R. L., Jialal, I., & Winter, W. E. (2012) · Tietz Textbook of Clinical Chemistry and Molecular Diagnostics · doi:10.1016/b978-1-4160-6164-9.00054-8 · Cited by 5
Phenotypic variation of 46,XX late identified congenital adrenal hyperplasia among Indonesians
Center for Biomedical Research (CEBIOR), F. O. M. D. U., Juniarto, A. Z., Ulfah, M., Ariani, M. D., Utari, A., & Faradz, S. M. (2018) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.033.01.02 · Cited by 5
Metadata
- Authors
- van der Kamp, H., & Wit, J.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-11-01
- Volume
- 151 Suppl 3
- Pages
- U71-U75
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2118556129
- Cited by
- 128
- References
- 27
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 9 · 2023: 3 · 2022: 4 · 2021: 7 · 2020: 5 · 2019: 9 · 2018: 5 · 2017: 9 · 2016: 7 · 2015: 6 · 2014: 10 · 2013: 7 · 2012: 10
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- congenital adrenal hyperplasia, newborn screening, 17-hydroxyprogesterone, cut-off values, preterm infants, false positives, prevalence, salt wasting, radioimmunoassay, ELISA, time-resolved fluoroimmunoassay
- MeSH terms
- Adrenal Hyperplasia, Congenital, Enzyme-Linked Immunosorbent Assay, False Positive Reactions, Female, Humans, Immunoenzyme Techniques, Infant, Newborn, Predictive Value of Tests, Radioimmunoassay, Neonatal Screening, 17-alpha-Hydroxyprogesterone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.